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The human B-lymphotropic virus (HBLV),' recently isolated from the periph-
eral blood of six patients affected by various hematological disorders (1), was
shown by detailed molecular and morphological characterizations to be a unique
member of the Herpesviridae family (2, 3). HBLV is an enveloped virus, 200 nm
in diameter, with an electron-dense icosahedral core composed of 162 capso-
mers (1, 3) containing a large double-stranded DNA genome (>110.000 bp). As
a result of these observations, the taxonomic designation human herpesvirus-6
(HHV-6) was proposed (4, 5). Despite extensive seroepidemiological studies and
attempts to obtain HBLV isolates from diversified patients, no definite etiolog-
ical association with human disease has been established to date.
HBLV can infect fresh normal mononuclear cells in vitro, yielding character-
istic morphologically altered lymphocytes, capable of surviving in culture for
15-20 d. Based primarily on the study of freshly isolated cells from infected
patients, a B lymphocyte tropism was initially suggested for HBLV (1). However,
subsequent in vitro studies demonstrated that HBLV could also infect cell lines
of various origins, including B and T lymphocytes, megakaryocytes, and glial
cells (4). In addition, two recent letters describing the isolation from African
patients of human herpesviruses genetically indistinguishable from HBLV also
suggested the infectability of other cell types (6, 7). Although in vitro studies
using established cell lines are not necessarily predictive of the in vivo cellular
tropism of a viral agent, the information so far available indicates that HBLV
may have a wide range of infectable cells.
In the present report we investigated further the in vitro cellular tropism of
HBLV using fresh normal mononuclear cells from various tissue sources.
Infected cells were subjected to extensive immunological and molecular
characterizations.
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PE, phycoerythryn; TCIDS, 50% tissue culture infectious dose; TdT, terminal deoxyribo-
nucleotydiltransferase.
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Materials and Methods
Source of Mononuclear Cells.
￿
Heparinized samples of adult peripheral blood, bone
marrow, and umbilical cord blood from healthy donors were collected under sterile con-
ditions. Tonsils and thymuses, obtained from children undergoing cardiac surgery inter-
ventions, were extensively minced and the cells in suspension were washed out with ster-
ile culture medium. Mononuclear cells (MN) from all sources were isolated by
centrifugation on Ficoll-Hypaque gradients (Pharmacia Fine Chemicals, Piscataway, NJ).
Source of Virus.
￿
HBLV was propagated in fresh, activated umbilical cord blood leu-
kocytes as previously described (1) . For the in vitro infection of mononuclear cells, either
conditioned medium from infected cord blood cultures or partially purified HBLV,
obtained by density banding on sucrose gradients, was used. The titer or 50% tissue cul-
ture infectious dose (TCIDbo) was determined by infecting triplicate cultures of activated
cord blood cells with serial 10-fold dilutions of the virus stock.
Infection of Mononuclear Cells In Vitro.
￿
Mononuclear cells, including the selected
CD2- or CD3- subpopulations (see below), were initially activated by cultivation for 24
h at 37°C in humidified 5% C02 atmosphere in culture medium (RPMI 1640) supple-
mented with 15% FCS and 1 gg/ml PHA-P. Cells were then washed, pelleted, resus-
pended in 2 ml stock HBLV (titer ^-109 TCIDao) and incubated for 2 h at 37°C. The
cells were subsequently washed and resuspended in culture medium supplemented with
10% FCS. 6-8 d after infection, dead cells were removed by Ficoll-Hypaque gradient
centrifugation and infected cells were cultured for additional 2-4 d, before immunolog-
ical or molecular characterizations. At that time, >90% of the cells were HBLV infected,
as detected by IFA (see below) or by in situ hybridization with the specific probe
pZVH14, as described (2).
Immunofluorescence Analysis. A wide panel of mouse mAbs and polyclonal antisera
were used to characterize HBLV-infected cells by either direct or indirect IFA, as pre-
viously described (1, 8). Purified unlabeled, FITC or phycoerythryn (PE)-conjugated
mAbs Leu-1, Leu-3a, Leu-4, Leu-7, Leu-9, Leu-11, Leu-M1, Leu-M2, Leu-M3, HPCA-
1, anti-TCR-a/,Q heterodimer (WT31), anti-IL-2-R, anti-leukocyte antigen (HLel) and
anti-CR2 were purchased from Becton Dickinson & Co. (Mountain View, CA) ; OKT3,
OKT4, OKT4a, OKT6, OKT8, OKT9, OKT11, OKDR, and OKBcALL from Ortho Phar-
maceutical (Raritan, NJ); MY7, MY9, B1, and B4 from Coulter Immunology (Hialeah,
FL); DRC and Kil from Dako Corp. (Santa Barbara, CA). Polyclonal rabbit anti-terminal
deoxynucleotydiltransferase (TdT) was obtained from Bethesda Research Laboratories
(Gaithersburg, MD); polyclonal goat anti-human IgG or IgM (y or J chain specific,
respectively) from Kirkegaard & Perry Laboratories, Inc. (Gaithersburg, MD). Human
sera containing specific antibodies towards HBLV were also used at 1 :40 dilution for
indirect IFA, after extensive absorption with HBLV- umbilical cord blood cells. Polyclo-
nal FITC-conjugated goat anti-mouse IgG or IgM, goat anti-rabbit IgG and goat anti-
human IgG antisera (Kirkegaard & Perry Laboratories, Inc.,) were used as second anti-
bodies. Cytoplasmic staining was carried out on cytocentrifuge preparations fixed for 10
min in cold acetone. Nuclear staining for TdT was performed on cytocentrifuge prepa-
rations fixed for 30 min in cold methanol. All samples were scored under a fluorescence
microscope (Leitz), counting >200 cells per test. Flow cytofluorometric analysis was per-
formed using a Becton Dickinson & Co. FACS (FRCS 440; Spectra Physics, Mountain
View, CA) equipped with an Argon laser. Live infected cells were treated for 1 h with
0 .5% paraformaldehyde before FACS analysis. Debris and dead cells were excluded from
the analysis by conventional scatter setting system. Fluorescein (green) and PE (red) emis-
sion lights were collected with band pass filters 530/30 and 575/26, respectively, and
logarithmically amplified. Isotype-matched mAbs of irrelevant specificity were used on
the same cells as negative controls.
Radio Immune Precipitation Assay (RIPA). HBLV-infected cord blood cells and the
control cell line ET62 were radioactively labeled by incubation for 18 h in medium con-
taining 50 gCi/ml ["S]cysteine. Labeled cells were washed in PBS and disrupted with 10
nM sodium phosphate (pH 7.2) containing 0.5% NaCI, 1% Triton X-100, 0 .5% sodium
deoxycholate and 0.1 % SDS (PBS-TDS) . The lysate was adsorbed overnight at room tem-LUSSO ET AL.
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perature with protein A-Sepharose. Immunoprecipitation analysis was performed by
addition to labeled and clarified extract (1 ml) of 5 Ag purified OKT3 mAb and 0.2 ml
of a 10% suspension of protein A-Sepharose bound to rabbit anti-mouse K light chain.
The samples were incubated overnight at 4°C. Immunoprecipitates were collected by cen-
trifugation, washed repeatedly in PBS-TDS, resuspended in Laemmli sample buffer,
heated for 2 min at 90°C, and analyzed by SDS-PAGE.
Northern Blot Analysis.
￿
Cellular RNA was extracted from HBLV-infected cord blood
MN cells and control cell lines by the guanidine isothiocyanate procedure, as previously
described (9) . Total cellular RNA (20 Ag/lane) was electrophoresed through 1 .2% for-
maldehyde-agarose gels and transferred to nylon membrane filters (Zeta Probe; Bio-Rad
Laboratories, Cambridge, MA). After baking for 2 h at 80°C, filters were hybridized at
37'C for 12 h to nick-translated probes in 4X SSC, 4X Denhardt's solution, 0.1% SDS,
50% formamide, 10% dextran sulfate, 50 mM sodium phosphate pH 6.5, 250 Ag/ml
yeast RNA. The filters were then washed two times in 2 X SSC/0.196 SDS at room tem-
perature and two times in 0.2X SSC/0.496 SDS at 65°C. The probes used for hybridiza-
tion were labeled by nick translation to a specificity of -lOs cpm/,ag and included TCR8
(Bgl II cDNA fragment derived from JUR-,B2 clone, coding for most of the C,#2 constant
domain, a kind gift of Dr. T. Mak, Ontario Cancer Institute, Toronto Canada), TCR-a
(cDNA clone pY14, a kind gift of Dr. T. Mak), TCR-y (derived from clone pTy-1, by
subcloning into Eco RI sites of pGEM4, a kind gift of Dr. D. Dialynas, Dept. of Bio-
chemistry and Molecular Biology, Harvard University, Cambridge, MA), and IgM heavy
chain (a genomic subclone of 1 .3 kb from the Eco RI site of CA 1 to the Eco RI site of
CA. 3 into the Eco RI site of pbr322, a kind gift of Dr. P. Leder, Dept. of Genetics,
Harvard Medical School, Boston, MA).
Immunoselection by Magnetic Microspheres. Monosized magnetic microspheres coated
with polyclonal goat anti-mouse IgG (DYNAL, Fort Lee, NJ) were used to isolate the
CD2- or CD3- cell subsets, as described (10). Briefly, freshly isolated umbilical cord
blood mononuclear cells (2 X 107) were incubated for 30 min at 4°C in PBS supple-
mented with 1% FCS with 2 Ag/ml of appropriate purified mAb. The cells were then
washed three times with cold PBS and incubated at 4°C under continuous rotation in
the presence of goat anti-mouse IgG-covered magnetic microspheres (40 :1, beads/puta-
tive positive cells ratio). After 40 min the rosetting and nonrosetting cell populations
were selected by placing the culture tube in contact with a cobalt-samarium magnet for
1 min and pipetting off the unbound cells. The proportion of residual CD2 + or CD3+
cells after this procedure was <I%, as detected by indirect immunofluorescence.
Complement-mediated Cellular Cytotoxicity. After treatment with magnetic beads, the
depletion of CD2+ or CD3 + mononuclear cells was completed by complement-mediated
cell lysis. CD2- or CD3-depleted subsets were incubated for 30 min at 4°C with the
appropriate mAb (OKTI l, OKT3, respectively, IgG2a subclass), washed three times, and
resuspended in rabbit complement (PelFreeze Biologicals, Rogers, AR) for 1 h under
continuous rotation. Cells were then washed three times in cold PBS and their viability
was tested by Trypan blue dye exclusion.
Results
In Vitro Infection of Fresh Mononuclear Cells with HBLV.
￿
Approximately 72 h
after infection of PHA-treated cells, characteristic HBLV-infected cells began to
appear within the cultures from all the tissue sources examined (Fig. 1). Little
or no infection was observed when MN cells were exposed to the virus without
previous in vitro activation by PHA. The morphologically altered infected cells
subsequently became the predominant population, since the majority of the
small, uninfected cells died within the first week in culture. The cell viability was
restored to >90% after removal of dead cells at day 6-8 by Ficoll-Hypaque
gradient centrifugation. After two more days in culture, >90% of the viable
cells were HBL', as evaluated by indirect IFA or by in situ hybridization. All1662 IN VITRO CELLULAR TROPISM OF HUMAN HERPESVIRUS-6
FIGURE: 1 .
￿
Characteristic electron microscopy appearance of an HBLV-infected T lympho-
cyte 8 d after infection . Mononuclear cells from normal human umbilical cord blood were
infected with HBLV 24 h after activation with PHA . Intranuclear and intracytoplasmic imma-
ture particles are recognizable, as well as mature virions outside the cell,
the immunological and molecular tests were carried out on these homogeneous
HBLV+ cell populations . In the early phases of infection (day 5-8), the viable
HBLV-infected cells demonstrated a consistent, albeit limited, spontaneous pro-
liferative activity (compared with unstimulated MN cells from the same donors,
as detected by [3H]thymidine incorporation, data not shown), but were unreac-
tive to PHA and/or IL-2 (either crude or recombinant preparations) added to
the cultures (data not shown) .
Immunological Analysis of HBLV-infected Cells . As illustrated in Table I,
HBLV-infected cells from normal adult peripheral blood, umbilical cord blood,
or thymic tissues displayed phenotypic characteristics of immature T lympho-
cytes, by either direct or indirect IFA . Analogous results were obtained after
infection of mononuclear cells from tonsil and bone marrow samples . The
results depicted in the table refer to day 8-10 homogeneous HBLV-infected cell
populations, but the same phenotypic pattern was also observed on single mor-
phologically altered lymphocytes during the early phases of culture infection .
Virtually all HBLV+ cells expressed the CD7 antigen, the earliest known T-lym-
phocytic marker along the intrathymic T cell differentiation pathway, the CD5
antigen, a pan-T marker, and the CD2 antigen, the receptor for sheep erythro-LUSSO ET AL.
TABLE I
Immunological Characterization of HBLV In Vitro-infected Cellsfrom Normal
HumanPeripheral Blood, Cord Blood, and Thymus
* Mean value of percent IFA positivity from different samples (>3).
I A low-intensity, diffuse cytoplasmic positivity was observed in the majority of the ele-
ments as detected on cytocentrifuge preparations fixedfor 10 min in cold acetone.
¢ mAbs used: OKBcALL, B4, 131, CR2;polyclonal anti-IgG andanti-IgM (y andAchain-
specific, respectively).
~~ Cytocentrifuge preparations were fixed for 30 min in cold methyl alcohol.
t Leu-M2, Leu-M3, OKM1, OKM5, MY7, MY9, DRC, Kil, Leu-7, Leu-11b, HPCA-1 .
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cytes, responsible for E-rosette formation. These cells also formed E-rosettes at
4°C in the presence of 25% FCS and 0.5% sheep erythrocytes (data not shown).
Other antigens detected on the majority of the cells were CD4, transferrin
receptor, and the leukocyte antigen HLe1, expressed at various intensities. A
limited proportion of infected cells (15-25%) also expressed the CD8 antigen.
Two-color immunofluorescence analysis showed that CD8+ cells consistently
coexpressed the CD4 antigen. The CD3 antigen, which appears on the cell sur-
face during the last phase of the intrathymic T cell maturation, was not detected
by IFA on the surface membrane but was weakly and diffusely expressed within
the cytoplasm of infected cells. An mAb reported to bind to a nonpolymorphic
region of the TCR-a/# heterodimer (WT31) (11), also yielded a weak cyto-
plasmic and no surface membrane signal. In addition to the above-mentioned
antigens, a proportion of infected cells also coexpressed class II MHC DR anti-
gens and the CD15 antigen (a granulocytic/monocytic marker also expressed by
the Reed-Sternberg cells and some activated T cells, reference 12). HBLV-
infected cells from all the sources studied did not display by IFA the early T cell
marker CD1. In addition, nuclear TdT was not detected by a polyclonal rabbit
antiserum on infected cells. Cells bearing B cell-associated antigens were only
Antigens mAb Adult PB Umbilical CB Thymus
CD1 OKT6 <1* <1 <1
CD2 OKT-11 94.4 97.0 90.1
CD3 OKT3 <lt <1 : <1"
CD4 Leu-3a 61.8 64.5 59.0
CD5 Leu-1 90.1 91.8 96.0
CD7 Leu-9 72.4 76.6 70.9
CD8 OKT8 26.7 15.7 25 .3
CD15 Leu-M1 11 .7 20 .0 8.8
CD25 IL-2-R <1 <1 <1
CD10, CD19,
CD20, CD21,
SIg, CIg§ <1 <1 <1
TCR WT31 <lI <lt <I'
DR OKDR 13.8 12.7 10.3
Leukocyte antigen HLel 95.5 97.4 91 .6
Transferrin
receptor OKT9 91 .8 95.3 90.1
NuclearTdT11 <1 <1 <1
Othersl <1 <1 <11664
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FIGURE 2 . Flow cytofluorometry
analysis of HBLV-infected cells from
normal human umbilical cord blood .
HBLV-infected cell populations (>
9096 HBLV' by indirect IFA with
infected patient sera or by in situ
hybridization with the RNA probe
pZVH14) were washed three times
in PBS and treated with FITC-con-
jugated (OKT11, OKT3, Leu-3a,
OKDR) or PE-conjugated (Leu-16,
Leu-12) mAbs. Cells were subse-
quently fixed with 0.596 paraformal-
dehyde and were analyzed . Dotted
lines represent the profiles obtained
with control, isotype-matched mAbs
or irrelevant specificity, conjugated
with the appropriate fluorochrome
for each test antibody . Green and
red emission lights were collected
with band pass filters 530/30 and
575/26, respectively, and logarith-
mically amplified .
occasionally observed and consistently represented <1% of the infected popu-
lation . A number of other antigens, characteristic of mononuclear phagocytic,
dendritic, natural killer, myeloid precursor, or Reed-Sternberg cells, were not
detected on infected cells . As shown in Fig. 2, fluorocytometric analysis of CD2,
CD3, CD4, CD19, CD20, and DR antigens confirmed the results obtained by
optical observation .
Radioimmunoprecipitation (RIP) by Anti-CD3 mAb.
￿
To confirm the IFA obser-
vation of low-level intracytoplasmic CD3 expression, an RIP assay was per-
formed after metabolic labeling of HBLV-infected cells with [s5S]cysteine . As
shown in Fig. 3, the mAb OKT3 precipitated the CD3 light (Mol mass ^-20 kD)
and heavy (25 kD) subunits, together with the associated ,B anda chains of TCR
of ^"43 and ^,49 kD, respectively .
Molecular Analysis ofT and B Cell-specific Gene Expression.
￿
To further confirm
the T cell origin of HBLV-infected cells, the expression of specific mRNA for
TCR-a, -ß, -y chains and Ig 1 heavy chains was studied . Fig . 4 depicts Northern
blot analysis of total cellular RNA derived from HBLV-infected cord blood cells
(lane A), the HTLV-I-infected T cell lines 702 and HUT-102 (lanes B and D,
FIGURE 3 . Radioimmunoprecipitation of ["°S]cysteine-labeled
human cord blood HBLV-infected cells and control EBV-trans-
formed B-lymphoblastoid human cell line ET62 . Cells were labeled
overnight with 50 ,uCi/ml of ["sS]cysteine and clarified lysates were
immunoprecipitated with mAb OKT3 . The precipitates were then
subjected to SDS-PAGE analysis, under reducing conditions .
(Lane 1) Cord Blood HBLV-infected cells ; (lane 2) ET-62 control
B cell line . The molecular weight standards (lane 3) include OVAL
(42 X 10"), carbonic anhydrase (31 X 10"), soybean trypsinogen
(21 .5 X 10") .LUSSO ET AL .
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FIGURE 4. Northern blot
analysis of TCR and IgM
RNA expression in HBLV-
infected cord blood cells. 20
kg of total cellular RNA
derived from HBLV-infected
cord blood cells (a and b, lane
A), HTLV-I-infected T cell
lines 702 (lane B) and HUT-
102 (lane D), and EBV-
infected B-lymphoblastoid
line RE (lane G) were electro-
phoresed under denaturing
conditions and transferred
onto nylon membrane filters .
The filters were probed with
cDNA fragment specific for
TCR-ß (a, t% panel), TCR-a
(a, bottom panel), TCR-y (b, bot-
tom panel), or a CIL-specific
genomic clone (b, top panel) .
18S and 28S ribosomal RNAs
are indicated as size markers.
respectively), and the EBV-infected B cell line RE (lane C) . Full-size TCR-a and
-0 messages were identified in HBLV-infected cord blood cells (Fig . 4 a, top and
bottom). TCR-^y transcripts were not detectable in these cells (Fig 4 b, bottom), but
were present in the control HTLV-I-infected T cell line 702 . Similarly, mRNA
for CA, was not identified in HBLV-infected cord blood cells, but was present in
the control B cell line RE (Fig . 4 b, top) . All lanes contained identical amounts
of total RNA, as verified by ethidium bromide staining of the RNA gel .
Infection of IL-2-dependent Cultured TLymphocytes.
￿
In addition to fresh normal
mononuclear cells, normal T lymphocytes expanded in vitro in the presence of
IL-2 for > 1 mo were successfully infected with HBLV (Fig . 5) . The yield of
infected cells from IL-2-dependent cultures was definitely lower than using
fresh mononuclear cells and progressively declined in long-term IL-2-stimulated
cultures . Very limited infection was indeed observed exposing the HBLV IL-2-
dependent T lymphocytes cultured in vitro for >60 d .
Infection of Selected Mononuclear Cell Subsets .
￿
To further address the question
of the origin and maturation level of HBLV target cells, CD2 - or CD3- MN
cell populations were obtained from human cord blood by means of immuno-
selection with mAbs and goat anti-mouse IgG-coated magentic microspheres,
followed by complement-mediated cell lysis . Control unfractionated MN cells
were exposed to rabbit complement alone, without previous mAb treatment .
Equal numbers of selected and unselected cells were subsequently activated with
PHA, infected with HBLV, and placed into culture, as described above . As illus-
trated in Fig. 6, the absolute number of HBLV-infected cells recovered from
the CD3- MN cell populations of three different donors 10 d after infection
was comparable to that from total MN cells (mean ± SD from 107 initial cells :
2.3 ± 0.3 X 106 from total MN cells vs . 2 .1 ± 0.7 X 106 from CD3-depleted
fractions) . By contrast, virtually no infected cells were detectable after 10 d in
CD2-depleted cell cultures (mean 0.1 ± 0.1 X 106 from 107 initial cells) .1666
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FIGURE 5 .
￿
Indirect immunfluorescence analysis of normal human peripheral blood T lym-
phocytes exposed to HBLV 40 d after establishment in culture. At day l the cells were stim-
ulated with PHA-P (1 jug/ml) and since day 4, delectinated IL-2 was regularly added at 10%
final dilution . Cytocentrifuge preparations were fixed in cold acetone for 10 min . Serum
from an HBLV+ human subject was used at 1 :40 dilution. FITC-conjugated polyclonal anti-
human IgG (f chain specific) antiserum was used as second layer antibody.
FIGURE 6 .
￿
Infection by HBLV of unselected
and selected mononuclear cell populations
from human cord blood . The number of
infected cells was evaluated at day 10 after
exposure to the virus of 10 7 fresh total (A),
CD3-depleted (B), or CD2-depleted ((,') mono-
nuclear cells . The percentage of infected cells
in the cultured population was established by
indirect immunofluorescence analysis with
positive human sera. The values are absolute
counts of infected cells and represent the
mean ± SD from three different cord blood
donors . The selection procedures by magnetic
microspheres followed by complement-
mediated cell lysis are given in Materials and
Methods .
Discussion
HBLV was originally isolated from the peripheral blood of six patients
affected by diverse apparently unrelated, hematological disorders (1) . A com-
mon feature of these patients was, however, a condition of immune deficiency,
either of iatrogenic origin (due to chemotherapeutic regimens) or caused by
their own primary diseases (two, for example, were HIV-1 infected). This abate-
ment of the immune defenses could account for the susceptibility to infection
by HBLV or for the activaton of latent virus. Recent seroepidemiological studiesLUSSO ET AL.
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by means of immunofluorescence techniques on fixed HBLV-infected cells
showed a widespread high prevalence of HBLV-specific antibodies in several
hematological disorders, of both neoplastic and non-neoplastic origin (Ablashi,
D. V., et al ., manuscript in preparation; Streicher, H. Z., et al., manuscript in
preparation). In particular, significant seropositivity was observed in various
lymphoproliferative disorders, advanced acquired immune deficiency syndrome
(AIDS), and the so-called chronic mononucleosis syndrome or chronic fatigue
syndrome (13).Inaddition,HBLV-specificDNAwasrecently identifiedbySouthern
blot analysis within the neoplastic tissues from three patients affected by non-
Hodgkin's lymphoma of B cell origin (14). Despite these observations, no
definitive evidence to date has linked HBLV to any specific clinical entity in
humans.
The present report demonstrates that HBLV is electively infectious for fresh
T lymphocytes in vitro and exerts on them a strong cytopathic effect. Despite
considerable efforts to elucidate the maturation stage of the T cells susceptible
to HBLV infection, it remains questionable whether they belong to a discrete,
quasimature differentiation phase or, conversely, are fully mature lymphocytes
undergoing important phenotypic and functional alterations after the interac-
tion with the virus. In this study, HBLV-infected T cells displayed some imma-
ture phenotypic characteristics (15). For example, they lack the surface mem-
brane TCR/CD3 complex and coexpress, at least partially, the CD4 and CD8
antigens. The simultaneous expression of these latter markers is characteristic
of the cortical thymic population, which is largely CD 1 + (16). The lack of CD I
determinants on HBLV-infected cells (included those derived from thymic tis-
sues) is not indicative per se, since it has recently been reported (17) that CD1
expression is not an indispensable intermediate step along the T cell differentia-
tion pathway outside the thymic environment.
In contrast with the immature phenotypic features, however, the analysis at
the RNA level demonstrated a mature pattern of TCR gene expression by
HBLV-infected cells. Indeed, HBLV-infected cells displayed full-size TCR-a and
-ß chain, but not -f chain mRNA, which is expressed at early stages of T cell
maturation (18). In addition, the nuclear TdT, another early T cell marker, was
negative on HBLV-infected cells. We attempted to address the question of the
maturation level of the HBLV target cells by infecting immunoselected mono-
nuclear cell populations. The results of these experiments indicate that at least
a consistent proportion of the susceptible cells resides within the CD3-, CD2+
immature T cell compartment. Another indication of immaturity is provided by
preliminary data from our laboratory, suggesting that HBLV-infected T cells are
unable to secrete the lymphokine IL-2 after stimulation in vitro with PHA and
phorbol esters.
As further evidence of the T cell tropism of HBLV, we also showed that nor-
mal T lymphocytes maintained in culture in the presence of IL-2 for > 1 mo
were easily infected. Furthermore, it was previously reported that several estab-
lished cell lines of various lineage origin, including T cells at early stages of dif-
ferentiation, could be infected by HBLV (19). In contrast, it is possibly relevant
that the T cell lines H9 and PEER, which are apparently refractory to HBLV
infection (Lusso, P., preliminary data), display a phenotype corresponding to an
advanced T cell maturation stage (surface CD3+).1668
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While it is clear from this study that T cells represent a major target for
HBLV infection, a linkage with B cell-related lymphoproliferative disorders is
suggested by the direct detection of HBLV in tumor tissues from non-Hodgkin
lymphomas of B cell type (14). This may suggest an indirect role for B cell tumo-
rigenesis as was hypothesized for HIV-1 (20, 21) or HTLV-I (22), presumably
acting through chronic antigenic stimulation and suppression of the T cell sur-
veillance on immune-activated or EBV-transformed B lymphocytic clones. In
light of the cellular tropism manifested by HBLV in vitro, we are currently
investigating the possible involvement of this virus in the pathogenesis ofvarious
T cell-related hematological disorders, as well as of neoplasms ofB lymphocytic
origin. In addition, due to the dramatic cytopathic effect exerted in vitro on T
lymphocytes, we are considering a possible role of HBLV in immunodeficiency
conditions.
Summary
We investigated the cellular tropism of human B-lymphotropic virus (HBLV)
(also designated Human Herpesvirus-6) in vitro by infecting fresh MN cells from
normal human adult peripheral blood, umbilical cord blood, bone marrow, ton-
sil, and thymus. Cultures from all the sources examined contained infectable
cells, as shown by the appearance of characteristic enlarged, round-shaped,
short-lived cells expressing HBLV-specific markers. Detailed immunological
analysis demonstrated that the vast majority of these cells expressed T cell-asso-
ciated antigens (i.e., CD7, CD5, CD2, CD4, and to a lesser extent, CD8). The
CD3 antigen and the TCR-a/0 heterodimer were not detectable on the surface
membrane, but were identified within the cytoplasm of HBLV-infected cells, by
both immunofluorescence and radioimmunoprecipitation assay. A proportion of
the HBLV-infected cell population also expressed the CD15 and class II MHC
DR antigens. By means of immunoselection procedures it was possible to show
that a consistent proportion of HBLV-infectable cells were contained within the
CD3-depleted immature T cell population, while the depletion of CD2+ cells
completely abrogated the infectability of the cultures. Northern blot analysis
confirmed the T cell origin of HBLV-infected cells, demonstrating the ex-
pression of full size TCR-a and -,B chain mRNA. In addition to fresh T cells,
HBLV was able to infect normal T lymphocytes expanded in vitro with IL-2 for
>30 d.
These results indicate that HBLV is selectively T cell tropic in the course of
the in vitro infection of normal mononuclear cells and may therefore be directly
involved in the pathogenesis of T cell related hematological disorders. In par-
ticular, in light of the cytopathic effect exerted in vitro on CD4+ T lympho-
cytes, a possible role of HBLV in immune deficiency conditions should be con-
sidered.
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